ALGS Sep 2024 5.000 call
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 4.3000 |
| Strike | 5.00 |
| Expire Date | 2024-09-20 |
| Day's Range | 0.0500 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
GlobeNewswireAligos Therapeutics Presents Positive Data at the EASL Congress 2024
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. The clinical poster presentations highlight the continued potent an
ZacksHere's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now
Aligos Therapeutics (ALGS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- GlobeNewswire
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy. The abstracts released t
